Abstract
Aim:
To characterize the in vitro bioactivities of rhodanine derivatives as novel peroxisome proliferator-activated receptor (PPAR) γ modulators, based on a hit (SH00012671) identified during high-throughput screening (HTS) of a diverse synthetic compound library, and to preliminarily elucidate the structure-activity relationship of this class of PPARγ agonists.
Methods:
Full-length PPARγ and retinoid X receptor α (RXRα), biotinylated PPAR response element (PPRE), [3H]BRL49653 (rosiglitazone), and streptavidin-coated FlashPlate or microbeads were used to measure the receptor-binding properties of various compounds based on the scintillation proximity assay (SPA) technology. A recombinant PPRE vector was transiently cotransfected with PPARγ and RXRα plasmids into the African green monkey kidney (CV-1) cells, and the effects of BRL49653 and test compounds on transcription mediated by PPARγ were determined by examining luciferase (reporter) responses. 3T3-L1 cells were employed to determine whether the compounds facilitated adipogenesis upon PPARγ activation.
Results:
Of the 16 000 samples screened with the SPA method, only 1 compound (SH00012671) displayed a similar binding affinity (Ki=186.7 nmol/L) to PPARγ as BRL49653, but it was inactive in the cell-based assays. A series of rhodanine derivatives were synthesized based on the core structure of SH00012671 and 8 of them showed agonist activities in both cotransfection and pre-adipocyte differentiation assays. To reduce intrinsic cytotoxicities, the sulphur on the rhodanine was changed to oxygen. This alteration led to a decrease in receptor-binding affinities while modified analogues generally maintained agonist efficacies in the cell-based assays. Of the analogues studied, compound 31 exhibited about 70% the efficacy exerted by BRL49653 in both cotransfection and pre-adipocyte differentiation assays.
Conclusion:
Through minor chemical modifications on the core structure of the initial HTS hit, SH00012671 was transformed to possess both molecular (PPARγ binding) and cellular (adipogenesis) activities. The rhodanine derivatives reported here may represent a new scaffold in further understanding the molecular mechanism of agonism at PPARγ.
Similar content being viewed by others
Article PDF
Change history
06 July 2018
This article was initially published with an incorrect DOI. A new DOI has been assigned and registered at Crossref, and has been corrected in the article.
References
Wilson TM, Wahli W . Peroxisome proliferators-activated receptor agonists. Curr Opin Chem Biol 1997; 1: 235–41.
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W . Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 1996; 137: 354–66.
Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355–9.
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM . Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771–4.
Ijpenberg A, Jeannin E, Wahli W, Desvergne B . Polarity and specific sequence requirements of PPAR-RXR heterodimer binding to DNA: a functional analysis of the malic enzyme gene PPRE. J Biol Chem 1997; 272: 20108–17.
Aubry CJ, Pernin A, Favez T, Burger AG, Wahli W, Meier CA, et al. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements: importance of the 5′ flanking region. J Biol Chem 1997; 272: 25 252–9.
Keller JK, Collet P, Bianchi A, Huin C, Kremarik PB, Becuwe P, et al. Implications of peroxisome proliferator activated receptors (PPAR) in development, cell life status and disease. Int J Dev Biol 2000; 44: 429–42.
Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeada H . Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung 1990; 40: 37–42.
Kletzien RF, Clarke SD, Ulrich RG . Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992; 41: 393–8.
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA . An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators-activated receptor gamma (PPARy). J Biol Chem 1995; 270: 12 953–6.
Javiya VA, Patel JA . The role peroxisome proliferator-activated receptors in human disease. Edu Forum 2006; 38: 243–53.
Wu B, Gao J, Wang MW . Development of a complex scintillation proximity assay for high-throughput screening of PPARγ modulators. Acta Pharmacol Sin 2005; 26: 339–44.
Gearing KL, Göttlicher M, Teboul M, Widmark E, Gustafsson J . Inter-action of the peroxisome proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 1993; 90: 1440–4.
Tadashi S, Masaki O . Studies on sulfur-containing heterocyclic compounds. II. Reaction of potassium 3-benzoyldithiocarbazate and monochloroacetic acid and its ester. J Pharm Soc Japan 1955; 75: 1535–9.
Cheng Y, Prusoff WH . Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099–108.
Amit K, Sushil KK, Anil KS . QSAR and molecular modeling studies in imidazopyridinethiazolidine-2,4-diones: PPARγ agonists. Med Chem Res 2004; 13: 770–80.
Kwang RK, Jeong HL, Seung JK, Sang DR, Won HJ, Sung-Don Y, et al. KR-62980: A novel peroxisome proliferator-activated receptor γ agonist with weak adipogenic effects. Biochem Pharmacol 2006; 72: 446–54.
Béatrice D, Walter W . Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–88.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported in part by grants from the Shanghai Municipality Science and Technology Development Fund (No 05dZ22914 and 06DZ22907) and the Ministry of Science and Technology (No 2004CB518902).
Rights and permissions
About this article
Cite this article
Liu, Q., Zhang, Yy., Lu, Hl. et al. Rhodanine derivatives as novel peroxisome proliferator-activated receptor γ agonists. Acta Pharmacol Sin 28, 2033–2039 (2007). https://doi.org/10.1038/aps2007250
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/aps2007250
Keywords
This article is cited by
-
Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay
Acta Pharmacologica Sinica (2013)